Qrxpharma Ltd (QRXPF) 0.0010 $QRXPF
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against QRx Pharma, Ltd. on Behalf of Investors
BusinessWire - Thu Aug 13, 8:53PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by QRx Pharma, Ltd. ("QRx" or the "Company"
(OTC: QRXPY) (OTC: QRXPF). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
GPM Announces the Filing of a Securities Class Action on Behalf of QRx Pharma, Ltd. Investors
BusinessWire - Wed Aug 12, 10:05AM CDT
Glancy Prongay & Murray LLP ("GPM" announces the filing of a class action lawsuit on behalf of investors of QRx Pharma, Ltd. ("QRX" or the "Company" (OTC Ticker: QRXPY; QRXPF), who purchased shares between January 24, 2011 and April 23, 2014, inclusive (the "Class Period" . QRX investors have until August 21, 2015 to file a motion to serve as lead plaintiff in the class action.
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd. -- QRXPY, QRXPF
GlobeNewswire - Thu Jul 30, 3:37PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY) (OTC:QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.
ALERT: The Rosen Law Firm Reminds QRx Pharma, Ltd. Investors of the Important Deadline in the Class Action - QRXPY, QRXPF
BusinessWire - Fri Jul 10, 2:30PM CDT
The Rosen Law Firm, a global investor rights law firm, reminds purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" of the important August 24, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.
INVESTOR ALERT: Investigation of QRx Pharma, Ltd., Announced by Glancy Prongay & Murray LLP
BusinessWire - Mon Jul 06, 10:14AM CDT
Glancy Prongay & Murray LLP announces an investigation on behalf of investors of QRx Pharma, Ltd. ("QRx Pharma" or the "Company" (OTC Ticker: QRXPY; QRXPF) concerning whether the Company misled investors regarding the potential approval of its drug products. Glancy Prongay & Murray is preparing to file a complaint to recover damages on behalf of QRx Pharma investors, and investors are encouraged to contact the firm to discuss the matter.
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd.
BusinessWire - Mon Jun 29, 4:57PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws.
Hemorrhage Pipeline Review 2015 - 6 Companies & 9 Drug Profiles
M2 - Thu May 21, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vsfdh6/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellphire, Inc. - Digna Biotech, S.L. - Haemostatix Ltd - QRxPharma Limited - Serendex Pharmaceuticals A/S - Thrombotargets Corporation Drug Profiles - DB-055 - eptacog alfa - PeproStat - Protein for Hematological Disorders, Dermatology, Shock and Injury - Q-8008 - Thrombosomes - TT-111 - TT-112 - V-0801 For more information visit http://www.researchandmarkets.com/research/vsfdh6/hemorrhage
Hemorrhage - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjlpxn/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H2 2013" report to their offering. 'Hemorrhage - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Hemorrhage - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhage pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemorrhage. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Grifols, S.A. - Digna Biotech, S.L. - Thrombotargets Corporation - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/fjlpxn/hemorrhage
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 5.73 (+0.15), KNMD: (), OPK: 10.03 (+0.02), PFE: 34.93 (+0.24), AZN: 29.87 (+0.14), GSK: 42.85 (-0.04), FOLD: 7.16 (-0.01), NVS: 81.31 (+0.36)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against QRx Pharma, Ltd. on Behalf of Investors
BusinessWire - Thu Aug 13, 8:53PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by QRx Pharma, Ltd. ("QRx" or the "Company"
(OTC: QRXPY) (OTC: QRXPF). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. GPM Announces the Filing of a Securities Class Action on Behalf of QRx Pharma, Ltd. Investors
BusinessWire - Wed Aug 12, 10:05AM CDT
Glancy Prongay & Murray LLP ("GPM"
announces the filing of a class action lawsuit on behalf of investors of QRx Pharma, Ltd. ("QRX" or the "Company" (OTC Ticker: QRXPY; QRXPF), who purchased shares between January 24, 2011 and April 23, 2014, inclusive (the "Class Period" . QRX investors have until August 21, 2015 to file a motion to serve as lead plaintiff in the class action. EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd. -- QRXPY, QRXPF
GlobeNewswire - Thu Jul 30, 3:37PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY) (OTC:QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws. ALERT: The Rosen Law Firm Reminds QRx Pharma, Ltd. Investors of the Important Deadline in the Class Action - QRXPY, QRXPF
BusinessWire - Fri Jul 10, 2:30PM CDT
The Rosen Law Firm, a global investor rights law firm, reminds purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period"
of the important August 24, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws. INVESTOR ALERT: Investigation of QRx Pharma, Ltd., Announced by Glancy Prongay & Murray LLP
BusinessWire - Mon Jul 06, 10:14AM CDT
Glancy Prongay & Murray LLP announces an investigation on behalf of investors of QRx Pharma, Ltd. ("QRx Pharma" or the "Company"
(OTC Ticker: QRXPY; QRXPF) concerning whether the Company misled investors regarding the potential approval of its drug products. Glancy Prongay & Murray is preparing to file a complaint to recover damages on behalf of QRx Pharma investors, and investors are encouraged to contact the firm to discuss the matter. EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against QRx Pharma, Ltd.
BusinessWire - Mon Jun 29, 4:57PM CDT
The Rosen Law Firm, a global investor rights law firm, announces that the filing of a class action lawsuit on behalf of purchasers of QRx Pharma, Ltd. (OTC:QRXPY, QRXPF) American Depository Shares from January 24, 2011 through April 23, 2014, both dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for QRx Pharma investors under the federal securities laws. Hemorrhage Pipeline Review 2015 - 6 Companies & 9 Drug Profiles
M2 - Thu May 21, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vsfdh6/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellphire, Inc. - Digna Biotech, S.L. - Haemostatix Ltd - QRxPharma Limited - Serendex Pharmaceuticals A/S - Thrombotargets Corporation Drug Profiles - DB-055 - eptacog alfa - PeproStat - Protein for Hematological Disorders, Dermatology, Shock and Injury - Q-8008 - Thrombosomes - TT-111 - TT-112 - V-0801 For more information visit http://www.researchandmarkets.com/research/vsfdh6/hemorrhage
Hemorrhage - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjlpxn/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H2 2013" report to their offering. 'Hemorrhage - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Hemorrhage - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhage pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemorrhage. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Grifols, S.A. - Digna Biotech, S.L. - Thrombotargets Corporation - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/fjlpxn/hemorrhage
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 5.73 (+0.15), KNMD: (), OPK: 10.03 (+0.02), PFE: 34.93 (+0.24), AZN: 29.87 (+0.14), GSK: 42.85 (-0.04), FOLD: 7.16 (-0.01), NVS: 81.31 (+0.36)
